Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data

By C. Rudin, J. Poirier, L. Byers, C. Dive, A. Dowlati, J. George, J. Heymach, Jane E. Johnson, J. Lehman, D. MacPherson and 8 more. Nature Reviews. Cancer, 2019

1,052 citations recorded by the source corpus.

Subfields: Epidemiology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/20ff2e7974e3a35938339aef366aa0e61c3e5d83

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Mauro Papotti

In Molecular Biology

1. Paul Robson
2. Yuanxin Xi

In Oncology

1. Jing Wang

Citations in the corpus

• Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities (2021, background): “The consensus definition of SCLC subtypes has evolved from classic/variant to neuroendocrine (NE)/nonneuroendocrine (non-NE) to transcription factor defined subsets (Carney et al., 1985; Gazdar et al., 1985; Rudin et al., 2019; Zhang et al., 2018).”
• Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms (2022, background): “Pulmonary SCNECs have recently been subclassified based on ASCL1, NEUROD1, POU2F3, and YAP1 expression into four major potentially clinically relevant classes [79, 80].”